Enanta Pharmaceuticals Inc (ENTA)

[gdollasign]

however, the lack of certainty is based on the data from GILD’s ION-3 study compared to the ION-1 study (#msg-95103023, #msg-96696670) rather than the report of one patient who relapsed after an 8-week treatment course.

Sure, of course. Just seems like a data point not widely known. And, I am always looking for a GILD chink in the armor..so to speak.